Working… Menu
Trial record 2 of 6 for:    nash emricasan

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis (ENCORE-LF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03205345
Recruitment Status : Unknown
Verified March 2019 by Conatus Pharmaceuticals Inc..
Recruitment status was:  Active, not recruiting
First Posted : July 2, 2017
Last Update Posted : March 19, 2019
Information provided by (Responsible Party):
Conatus Pharmaceuticals Inc.